Full-Time
HSE & Sustainability Data Manager
Posted on 11/5/2025
Waters Corporation
10,001+ employees
Analytical instruments, software, and services provider
No salary listed
Franklin, MA, USA + 1 more
More locations: Trafford, UK
Hybrid
Three days on-site per week at Milford, MA.
 Data & Analytics (2) |
|---|
| , |
- Minimum of 7 years of experience in data analysis, reporting, or metrics development within a Health, Safety, and Environment or compliance-focused environment
- Bachelor’s Degree or above
- Relevant coursework in data analysis, computer science, data extraction, data exploration and data visualization
- Basic Knowledge of web development platforms, databases, and infrastructure
- Strong analytical, problem-solving, and project management skills
- Strong communication, interpersonal, and organizational skills
- Develop and implement global data governance frameworks for HSE and sustainability metrics
- Develop and implement a standardized process for integrating data into all management software
- Establish and maintain protocols for monitoring and maintaining the integrity and transparency of data intake and validation processes
- Own and manage global HSE and sustainability software platforms (e.g., Intelex, Power BI, Celonis)
- Lead system integration with HR and IT platforms and oversee troubleshooting and upgrades
- Conduct strategic analysis of current and future HSE and Sustainability data systems’ needs to enhance existing data management and reporting requirements
- Serve as the Subject Matter Expert for HSE & sustainability platforms
- Manage the monthly & quarterly data collection process for metrics and reporting of Sustainability and HSE data
- Develop and produce regular and ad-hoc reports, dashboards and presentations to support the oversight and management of key metrics, indicators, and trends
- Analyze HSE and sustainability data to identify trends, patterns, areas for improvement, and provide insights and recommendations to management for enhancing the company's HSE and Sustainability performance
- Implement automation and process enhancements to streamline data workflows
- Lead HSE and sustainability software and data migration strategies for M&A integrations, including creating harmonized reporting processes and governance across the combined portfolio
- Support the team in the development of risk mitigation strategies based on data driven insights
- Incorporate new metrics and data sources to provide a more comprehensive view of HSE & Sustainability performance
- Partner with global teams to resolve issues and ensure data integrity
- Provide data driven insights to guide capital planning, workplace strategies, and sustainability roadmaps
- Experience using Intelex, Power BI, and Celonis software platforms, preferred
- Prior experience with HSE data collection and metrics is a plus
Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.
Company Size
10,001+
Company Stage
IPO
Headquarters
Milford, Connecticut
Founded
1958
Simplify's Take
What believers are saying
- Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
- Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
- China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.
What critics are saying
- Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
- $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
- BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.
What makes Waters Corporation unique
- BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
- omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
- ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Company News
Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.
Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.
Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.
Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.
Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.